Live Analyst Rating Changes 1942 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Gil Blum
NDM
Gil Blum
Wall Street Analyst
★★★☆☆
#1658
on 13Foresight · ranked by our own returns
40%
Success Rate
+4.2%
Average Return
10 of 25 calls profitable · +1.3% vs benchmark
📈 Across the calls we could measure, roughly 40% of Gil Blum's ratings turned a profit when each position was held for 1 year — averaging +4.2% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

146 Buy 27 Hold 11 Sell
Gil's Stock Coverage 27 ratings · 2026-06-23
Company Date Position Consensus Price Target 1-Yr Return
LYEL
Lyell Immunopharma
Jun 15, 2026 BUY Buy
+103.3% avg upside
10 analysts
$44.00
266.27% Upside
·
NRIX
Nurix Therapeutics
Jun 15, 2026 BUY Strong Buy
+66.8% avg upside
26 analysts
$34.00
82.11% Upside
·
RNAC
Cartesian Therapeutics
Jun 09, 2026 BUY Strong Buy
+220.1% avg upside
19 analysts
$40.00
304.39% Upside
+0.0%
ARTV
Artiva Biotherapeutics, Inc.
Jun 08, 2026 BUY Strong Buy
+251.1% avg upside
7 analysts
$41.00
334.30% Upside
+52.1%
FATE
Fate Therapeutics
Jun 04, 2026 HOLD Buy
+465.3% avg upside
31 analysts
-10.4%
CELC
Celcuity
Jun 02, 2026 BUY Strong Buy
+37.9% avg upside
16 analysts
$157.00
72.57% Upside
-4.0%
IMCR
Immunocore Holdings
Jun 01, 2026 BUY Strong Buy
+121.4% avg upside
22 analysts
$75.00
155.02% Upside
·
AUTL
Autolus Therapeutics
May 14, 2026 BUY Strong Buy
+611.3% avg upside
16 analysts
$10.00
568.84% Upside
-8.2%
SLDB
Solid Biosciences
May 14, 2026 BUY Strong Buy
+91.0% avg upside
23 analysts
$19.00
129.50% Upside
-9.3%
NKTX
Nkarta
May 13, 2026 BUY Strong Buy
+561.5% avg upside
15 analysts
$11.00
292.81% Upside
-13.7%
MREO
Mereo Biopharma Group Plc
May 12, 2026 BUY Strong Buy
+1092.6% avg upside
11 analysts
$3.00
814.69% Upside
-4.0%
ABSI
AbSci
May 08, 2026 BUY Strong Buy
+23.0% avg upside
18 analysts
$7.00
16.85% Downside
+25.6%
RCKT
Rocket Pharmaceuticals
May 08, 2026 HOLD Buy
+381.9% avg upside
29 analysts
-18.5%
RXRX
Recursion Pharmaceuticals
May 07, 2026 BUY Buy
+146.7% avg upside
12 analysts
$8.00
151.48% Upside
-4.9%
SRPT
Sarepta Therapeutics
May 07, 2026 SELL Buy
+241.4% avg upside
49 analysts
+24.3%
TCRX
TScan Therapeutics
May 06, 2026 BUY Strong Buy
+868.3% avg upside
12 analysts
$6.00
590.10% Upside
-29.4%
TSHA
Taysha Gene Therapies
May 06, 2026 BUY Strong Buy
+99.1% avg upside
21 analysts
$12.00
81.81% Upside
-8.0%
GERN
Geron
May 06, 2026 BUY Strong Buy
+228.8% avg upside
19 analysts
$4.00
194.05% Upside
-9.5%
CRSP
Crispr Therapeutics AG
May 05, 2026 BUY Buy
+38.2% avg upside
41 analysts
$82.00
51.20% Upside
+3.0%
STTK
Shattuck Labs
Nov 07, 2025 HOLD Strong Buy
+350.9% avg upside
14 analysts
+118.7%
NBP
NovaBridge Biosciences
Oct 24, 2025 HOLD Strong Buy
+1289.1% avg upside
14 analysts
·
NXTC
NextCure
Dec 27, 2024 HOLD Strong Buy
+909.8% avg upside
10 analysts
+29.8%
GB:0DPB
Bavarian Nordic AS
Feb 16, 2023 BUY Strong Buy
+101.1% avg upside
5 analysts
$371.00
111.30% Upside
·
TECX
Tectonic Therapeutic
Dec 07, 2022 BUY Strong Buy
+86.3% avg upside
24 analysts
$6.00
80.40% Downside
+78.2%
SYRE
Spyre Therapeutics
Aug 25, 2022 HOLD Strong Buy
-23.7% avg upside
23 analysts
·
ATHXQ
Athersys
Jun 03, 2022 HOLD Buy
+29964185.7% avg upside
8 analysts
-84.0%
GNCAQ
Genocea Biosciences
Apr 06, 2022 BUY Strong Buy
+573999900.0% avg upside
10 analysts
$6.00
599999899.96% Upside
·
🔒 22 more ratings — with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Gil Blum — Frequently Asked Questions
How accurate are Gil Blum's stock ratings?
Based on the calls 13Foresight could measure, about 40% of Gil's ratings were profitable over a one-year hold, with an average return of +4.2% per rating, or +1.3% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Gil ranked on 13Foresight?
Gil Blum is currently ranked #1658 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Gil cover?
Gil most recently has ratings on LYEL, NRIX, RNAC, ARTV, FATE, CELC, IMCR, AUTL, SLDB, NKTX, MREO, ABSI and 15 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.